Novavax

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. 

CEO
John C.s Jacobs
CEOJohn C.s Jacobs
Employees
952
Employees952
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1987
Founded1987
Employees
952
Employees952

NVAX Key Statistics

Market cap
1.31B
Market cap1.31B
Price-Earnings ratio
3.59
Price-Earnings ratio3.59
Dividend yield
Dividend yield
Average volume
4.75M
Average volume4.75M
High today
$8.48
High today$8.48
Low today
$8.02
Low today$8.02
Open price
$8.23
Open price$8.23
Volume
6.18M
Volume6.18M
52 Week high
$11.55
52 Week high$11.55
52 Week low
$5.01
52 Week low$5.01

NVAX News

Simply Wall St 3d
What Shah Capital’s Push for a Sale Means for Novavax Shares in 2025

Thinking of what to do with Novavax stock? You are definitely not alone. Whether you've held on through its wild swings or are eyeing it on this latest upswing,...

What Shah Capital’s Push for a Sale Means for Novavax Shares in 2025
Benzinga 4d
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19...

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
TipRanks 5d
Shah Capital pushes for Novavax’s sale on underperformance, Reuters says

Shah Capital has urged Novavax’s (NVAX) board to pursue a sale of the biotech, citing a third consecutive year of poor roll-out of its COVID-19 shot, the hedge...

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
14.3%
Sell
28.6%

More NVAX News

Simply Wall St 5d
Novavax Valuation in Focus After Sanofi Deal Unlocks Milestone Payments and Royalty Potential

Novavax (NVAX) has just completed the transfer of marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi in the European Union. This move unlock...

Novavax Valuation in Focus After Sanofi Deal Unlocks Milestone Payments and Royalty Potential

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.